A steady rate of technology development in coronary stents, producing an equally steady stream of new stent market introductions, is focused on expanding aggregate stent caseload (through penetration of what would otherwise be coronary artery bypass caseload) or shifting the balance even further toward concentration of stents sales to the drug-eluting stent (DES) variety. While [...]
Stenting is not ideal for all patients with coronary heart disease, such as those with left main or three (or more) vessel disease. However, the vast majority of cardiovascular disease patients can benefit from the benefits of PCI, not the least of which include a shorter recovery period and less trauma to the patient. The [...]
Dr. Julio Palmaz, who with Dr. Richard Schatz patented the balloon-expandable stent, believes that, while the market for stents has evolved from bare metal stents to drug-eluting stents (DES), the inevitable limitation of DES will be that they lead to inflammatory response and that their real drawback is that they create a barrier between tissue [...]
The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India): [...]
(The global market for coronary stents worldwide is assessed in the MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017.") The market for coronary stents in Asia and the Pacific region contains both China (early technology adopters) and Japan (with a longer regulatory approval cycle), which generated a combined [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years. The local market forces dictating these differences include: Regulatory timelines in [...]
My posts on advanced medical technology, drawing frequently from our market reports, are worth emphasizing for their global perspective. Some two decades ago, it became apparent to me that that the global market perspective is not reserved for big, multi-national companies and their global presence. My understanding of this came about from the experience of [...]
The coronary stent market has represented a marvelous opportunity for many medical technology companies, but even though it is a huge market now, and has generated enormous cash flow for early entrants, it runs significant risk for current manufacturers as well as those seeking to gain share of this multi-billion dollar global market. The reason [...]
In the $7 billion+ worldwide market for drug-eluting coronary stents, a consistent theme is now the myriad challenge to existing players from the host of emerging competitors, particularly since the advent of drug-eluting stents (DES). Although not so long ago the DES market was monopolized by J&J/Cordis, then split and controlled by J&J and Boston [...]
The evolution of the coronary stent market, like most medical device markets, has been driven by manufacturers focused on expanding the use of coronary stents into new caseload as well as penetrating the market shares of competitors. Clinicians, for their turn as gatekeepers in this effort, are guided in the adoption of stent technologies [...]
Contact:
